AMD

The research marks the first attempt at integrating a photoactivatable anti-angiogenic agent with a photosensitizer into a single nanoformulation for AMD treatment.

Randomization has been completed and, according to the company, topline data is expected during the third quarter of 2024.

Umedaptanib pegol has potential to improve outcomes if used as a first-line medication prior to patients receiving treatments targeting VEGF.

Retina experts deliberate on the role of fluorescein angiography in AMD and discuss initiation of anticomplement therapy for geographic atrophy in conjunction with anti-VEGF therapy for neovascular AMD.

Roger Goldberg, MD, presents a case of a patient showing signs of geographic atrophy who subsequently develops nAMD and highlights the favorable outcomes achieved through anti-VEGF therapy.

According to the company, OCU410 is a modifier gene therapy product candidate being developed for dry AMD

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD.

Japanese investigators may have found a way of predicting which patients will develop intraocular inflammation in retrospective study.

Both oxidative stress and HIF-1 have been previously implicated in the development of AMD, but this research more clearly shows how cells are affected.

The predictive factors were the previous number of anti-vascular endothelial growth factor and the photometry laser flare-cell (LFCP) value.

The expert panel discusses what constitutes treatment failure in anti-VEGF therapy for nAMD and examines how various treatments may yield varying results in managing PED.

Adrienne Scott, MD, presents a case of neovascular AMD with PED in a patient who experiences a stroke while on anti-VEGF therapy.

A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD.

The investigators wanted to determine if subclinical changes in the blood–aqueous barrier and the retinal physiology developed after anti-VEGF treatments with aflibercept, brolucizumab, and or faricimab .

The company announced key secondary endpoints were achieved with both EYP-1901 doses. These include a more than 80% reduction in treatment burden, with nearly two-thirds of eyes supplement-free up to 6 months.

The ranibizumab biosimilar is a recombinant antigen-binding fragment (Fab).

The company announced a resubmission of the ONS-5010 BLA on track for the end of calendar year 2024, pending final agreement on a clinical trial protocol with the FDA and successful completion of the required additional clinical trial.

Expert retina specialists deliberate on their approach to treating DME, emphasizing their primary treatment choice and cases where they would use PRP laser therapy and steroids alongside anti-VEGF treatments.

Carl Danzig, MD, presents a case involving a patient with both DME and PDR, showcasing the impressive anatomic improvement achieved by treating with a dual anti-VEGF and Ang2 inhibitor.

By joining the group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD, RetinAI hopes to forge a global retinal imaging initiative targeting research in the disease.

The augmented reality headset compensates for central vision loss to enhance the visual clarity of patients with age-related macular degeneration and other conditions such as Stargardt disease.

Rishi Singh, MD, discusses the criteria for identifying patients who would benefit from biosimilar therapy.

Rishi Singh, MD, presents a case of neovascular age-related macular degeneration and diabetic macular edema demonstrating how the use of ranibizumab biosimilars can yield remarkable anatomical improvements comparable to those expected with reference biologics.

Rishi Singh, MD, provides an overview of biosimilars in the context of retinal diseases and discusses their significance within the healthcare system.